Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2004 Mar;55(3):306-19.
doi: 10.1002/ana.20009.

Imaging Brain Amyloid in Alzheimer's Disease With Pittsburgh Compound-B

Comparative Study

Imaging Brain Amyloid in Alzheimer's Disease With Pittsburgh Compound-B

William E Klunk et al. Ann Neurol. .


This report describes the first human study of a novel amyloid-imaging positron emission tomography (PET) tracer, termed Pittsburgh Compound-B (PIB), in 16 patients with diagnosed mild AD and 9 controls. Compared with controls, AD patients typically showed marked retention of PIB in areas of association cortex known to contain large amounts of amyloid deposits in AD. In the AD patient group, PIB retention was increased most prominently in frontal cortex (1.94-fold, p = 0.0001). Large increases also were observed in parietal (1.71-fold, p = 0.0002), temporal (1.52-fold, p = 0.002), and occipital (1.54-fold, p = 0.002) cortex and the striatum (1.76-fold, p = 0.0001). PIB retention was equivalent in AD patients and controls in areas known to be relatively unaffected by amyloid deposition (such as subcortical white matter, pons, and cerebellum). Studies in three young (21 years) and six older healthy controls (69.5 +/- 11 years) showed low PIB retention in cortical areas and no significant group differences between young and older controls. In cortical areas, PIB retention correlated inversely with cerebral glucose metabolism determined with 18F-fluorodeoxyglucose. This relationship was most robust in the parietal cortex (r = -0.72; p = 0.0001). The results suggest that PET imaging with the novel tracer, PIB, can provide quantitative information on amyloid deposits in living subjects.

Comment in

Similar articles

See all similar articles

Cited by 1,334 articles

  • Amyloid accumulation in Down syndrome measured with amyloid load.
    Zammit MD, Laymon CM, Betthauser TJ, Cody KA, Tudorascu DL, Minhas DS, Sabbagh MN, Johnson SC, Zaman SH, Mathis CA, Klunk WE, Handen BL, Cohen AD, Christian BT. Zammit MD, et al. Alzheimers Dement (Amst). 2020 Apr 16;12(1):e12020. doi: 10.1002/dad2.12020. eCollection 2020. Alzheimers Dement (Amst). 2020. PMID: 32435686 Free PMC article.
  • Down syndrome: Distribution of brain amyloid in mild cognitive impairment.
    Keator DB, Phelan MJ, Taylor L, Doran E, Krinsky-McHale S, Price J, Ballard EE, Kreisl WC, Hom C, Nguyen D, Pulsifer M, Lai F, Rosas DH, Brickman AM, Schupf N, Yassa MA, Silverman W, Lott IT. Keator DB, et al. Alzheimers Dement (Amst). 2020 Apr 17;12(1):e12013. doi: 10.1002/dad2.12013. eCollection 2020. Alzheimers Dement (Amst). 2020. PMID: 32435685 Free PMC article.
  • Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
    Malpetti M, Kievit RA, Passamonti L, Jones PS, Tsvetanov KA, Rittman T, Mak E, Nicastro N, Bevan-Jones WR, Su L, Hong YT, Fryer TD, Aigbirhio FI, O'Brien JT, Rowe JB. Malpetti M, et al. Brain. 2020 May 1;143(5):1588-1602. doi: 10.1093/brain/awaa088. Brain. 2020. PMID: 32380523 Free PMC article.
  • Imaging biomarkers in neurodegeneration: current and future practices.
    Young PNE, Estarellas M, Coomans E, Srikrishna M, Beaumont H, Maass A, Venkataraman AV, Lissaman R, Jiménez D, Betts MJ, McGlinchey E, Berron D, O'Connor A, Fox NC, Pereira JB, Jagust W, Carter SF, Paterson RW, Schöll M. Young PNE, et al. Alzheimers Res Ther. 2020 Apr 27;12(1):49. doi: 10.1186/s13195-020-00612-7. Alzheimers Res Ther. 2020. PMID: 32340618 Free PMC article. Review.
  • Brain amyloid, cortical thickness, and changes in activities of daily living.
    Vassilaki M, Aakre JA, Kremers WK, Lesnick TG, Mielke MM, Geda YE, Machulda MM, Knopman DS, Butler L, Traber M, Vemuri P, Lowe VJ, Jack CR Jr, Roberts RO, Petersen RC. Vassilaki M, et al. Ann Clin Transl Neurol. 2020 Apr;7(4):474-485. doi: 10.1002/acn3.51010. Epub 2020 Apr 21. Ann Clin Transl Neurol. 2020. PMID: 32314554 Free PMC article.
See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources